乳腺癌中CD44、CD133^+细胞表达及其与临床特征相关性研究

Relationship between CD44,CD133^+ cells expression and clinical characteristics in breast cancer

目的探讨乳腺癌中CD44、CD133+细胞表达与临床特征的相关性,为临床诊治、预后评估提供依据。方法收集乳腺病理标本200例(乳腺增生25例,不典型增生22例,乳腺癌153例)及正常乳腺组织30例。采用免疫组织化学染色测定乳腺不同病变组织中的CD44、CD133+表达情况,分析乳腺癌不同临床病理特征的CD44、CD133+表达水平。结果 CD44、CD133+在乳腺癌中的阳性表达率均明显高于乳腺增生、不典型增生(P<0.05)。在乳腺癌、乳腺增生、不典型增生中CD133+、CD44双重表达率分别为58.2%、32.0%、18.2%(P=0.00)。CD44、CD133+的表达水平随组织学分级、TNM分期的增高而升高(P<0.05);肿瘤复发的乳腺癌CD44、CD133+表达水平明显高于非复发的乳腺癌(P<0.05)。结论乳腺癌组织中CD44、CD133+的表达水平与乳腺癌临床病理特征存在存在一定相关性,因此,联合分析CD44、CD133+的表达有利于评估乳腺癌恶性程度和预后,也是乳腺癌治疗研究的一个方向。

Objective To investigate the relationship between CD44,CD133＋cells expression and clinical characteristics in breast cancer,which would provide basis for clinical diagnosis and treatment,prognosis. Methods The pathology specimens of 200 cases of breast（ 25 cases of breast hyperplasia,22 cases of atypical hyperplasia,153 cases of breast cancer） and 30 cases of normal breast tissue were included as the study subject. The CD44,CD133＋expression in different breast lesions were detected by immunohistochemical staining. The expression of CD44,CD133＋in different clinical and pathological characteristics of breast cancer were analyzed. Results The positive expression rate of CD44、CD133＋in breast cancer were both significantly higher than those of breast hyperplasia,atypical hyperplasia（ P 〈 0. 05）. The dual expression rate of CD133＋,CD44 in breast cancer,breast Hyperplasia,atypical hyperplasia was58.2%,32.0%,18.2%（ P =0.00）,respectively. The expression level of CD44,CD133＋increased with histological grade,TNM staging increasing（ P 〈 0. 05）. The expression level of CD44CD133＋in recurrent breast cancer was significantly higher than that in non recurrent breast cancer（ P 〈 0. 05）. Conclusion There was some correlation between expression levels of CD44,CD133＋and clinical pathological characteristics of breast cancer. Therefore,a combined analysis of CD44,CD133＋expression is useful for evaluation of malignant degree and prognosis of breast cancer,which can be a direction in study of breast cancer therapy.